17th ESO-ESMO Masterclass in Clinical Oncology

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Advisors: F. Lordick, DE - R. Popescu, CH


AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, lung, genito-urinary, gynaecological, head and neck cancers.
Workshops and spotlight sessions will facilitate compact update on communication skills, supporting and palliative care, immunotherapy, melanoma, sarcomas and GIST, treatment of elderly cancer patients, molecular tumour boards, magnitude of benefits scale, drug availability, biosimilars, adolescents and young adults, different roles in the oncology team, ethical dilemmas, low and high grade lymphomas.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the lunches with the experts and the networking aperitifs.
All participants will reside at the course venue and participation is compulsory throughout the whole course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills and ethical dilemmas workshops will be attended jointly.

THE MASTERCLASS IS
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

The Masterclass in Clinical Oncology is an ESO-ESMO joint event
The Masterclass is held in collaboration with the Flims Alumni Club
The 2018 Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

FACULTY
M. Aapro, Clinique de Genolier, Oncology Dpt., Genolier, CH
M. Andreoletti, European Institute of Oncology, Milano, IT
A. Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
G. Boniolo, University of Ferrara, Dept of Biomedical and Surgical Sciences, Ferrara, IT
l. Brugieres, Institut Gustave Roussy, Cancer in Young Adults, Paris, FR
P. Casali, National Cancer Institute, Medical Oncology Dpt., Milan, IT
F. Cavalli, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
G. Curigliano, European Institute of Oncology, Department of Medicine, Division of Experimental Therapeutics, Milano, IT
A. Dietz, University Hospital Leipzig, ENT Department, Leipzig, DE
M. Dreyling, Munich University Hospital, Medical Clinic III, Munich, DE
A. Eniu, Cancer Institute "Ion Chiricuta", Dept. of Breast Cancer, Cluj-Napoca, RO
C. Faivre-Finn, The Christie and University of Manchester, Institute of Cancer Sciences, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Cancer Center, Breast Unit, Rozzano, IT
S. Gillessen, Kantospital St. Gallen, Onco-Haematology Clinic, St Gallen, CH
S. Hillinger, University Hospital Zurich, Dept. of Thoracic Surgery, Zurich, CH
A. Hoy, Consultant in Palliative Medicine, Epsom, UK
F. Lordick, University Hospital Leipzig, University Cancer Center Leipzig, Leipzig, DE
M. Maio, Le Scotte Polyclinic, Siena, IT
P. Maugeri, University of Milan, Dept. of Experimental Oncology, Milan, IT
O. Michielin, Lausanne University Hospital - CHUV, Dept. of Medical Oncology, Lausanne, CH
R. Orecchia, European Institute of Oncology, Div. of Radiotherapy, Milan, IT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Breast Unit, Bellizona, CH
N. Pavlidis, University Hospital of Ioannina, Div. of Medical Oncology, Ioannina, GR
S. Peters, Centre Hospitalier Universitaire Vaudois, Dept. of Oncology, Lausanne, GR
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
G. Pruneri, University of Milan – European Institute of Oncology, Dept. of Pathology - Biobank for Translational Medicine Dpt., Milano, IT
M. Roobol, Erasmus University Medical Center, Dept. of Urology, Rotterdam, NL
V. Sanchini, European Institute of Oncology, Dept. of Biomedical Humanities, Milan, IT
M. Schmidinger, Medical University of Vienna, Internal Medicine Clinic I - Dept. of Oncology, Vienna, AT
D. Sebag-Montefiore, University of Leeds and Leeds Cancer Centre, Dept. of Oncology, Leeds, UK
J. Sehouli, Charité Medical University, Gynaecological Clinic, Berlin, DE
C. Sessa, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
R. Stahel, University Hospital Zurich, Cancer Center Zurich, Zurich, CH
E. Van Cutsem, University Hospital Leuven, Digestive Oncology Dpt., Leuven, BE
E. Van Muilekom, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Urology Dpt., Amsterdam, NL
J. Vermorken, Antwerp University Hospital, Dept. of Medical Oncology, Edegem, BE
C. Witt, University Hospital Zurich and University of Zurich, Inst. Complementary and Integrative Medicine, Zurich, CH

ORGANISING SECRETARIAT                       
Francesca Marangoni                            
Ph: +39 02 85464525                           
Email: fmarangoni@eso.net                        
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545

Applications
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net

ACCREDITATIONS
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 31 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
The Masterclass has been accredited with 25 Cat.1 ESMO MORA points.
The Masterclass has also received 47 points from the Landesärzteskammer Brandenburg (reserved to German participants).

ACKNOWLEDGEMENTS
The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are (as of June 2017):
• Platinum member: Astrazeneca, BMS
• Gold members: Eli Lilly, Helsinn, Merck KGaA, Darmstadt, Germany, Pfizer and Roche
• Silver members: Boehringer Ingelheim, Celgene Corporation, Genomic Health, Novartis Oncology, Sandoz Biopharmaceutical

SOCIAL MEDIA
Follow updates, send questions and join in the discussions using #18MCO on Twitter and Facebook.

 24 March

 25 March

 26 March

 27 March

 28 March

 29 March